VKTX Q3 Earnings Call Highlights Obesity Pipeline Progress - Zacks Investment Research
VKTX Q3 Earnings Call Highlights Obesity Pipeline Progress - Zacks Investment Research(摘要待生成)
VKTX Q3 Earnings Miss Estimates Amid Rising Clinical Expenses - Yahoo Finance
VKTX Q3 Earnings Miss Estimates Amid Rising Clinical Expenses - Yahoo Finance(摘要待生成)
Viking (VKTX) Q3 2026 Earnings Call Transcript
Viking reported a third-quarter 2026 net loss of $183.2 million, or $1.55 per share. [[fact-qkrthzhrn]] Third-quarter research and development expenses were $166.8 million, compared with $90 million in the year-earlier period. [[fact-67qnxpdsi]] At September 30, 2026, Viking held $960 million in cash, cash equivalents and short-term investments. [[fact-2vzz4goii]] The company closed concurrent public offerings of common stock and convertible notes, raising approximately $575 million in gross proceeds. [[fact-c3av6ho2y]] In the Phase II VENTURE study, weekly dosing produced mean weight reductions of up to 14.7% from baseline after 13 weeks. [[fact-3ab9t4f7g]] Viking said both VANQUISH studies were fully enrolled. [[fact-a6ahjsz09]]
Morgan Stanley and H.C. Wainwright reiterated VKTX Buy ratings
On Nov. 16, 2026, Michael Ulz of Morgan Stanley reiterated Buy with a $95 target; Joseph Pantginis of H.C. Wainwright reiterated Buy with a $102 target. The page listed consensus among 21 analysts as Strong Buy, with a $95.32 average target; it did not show prior targets for these actions.
VKTX shares fell despite new VK2735 data
On Nov. 16, 2026, VKTX was down about 5% at $27.75 when Benzinga published. The article said the Nov. 15 VENTURE analysis added detail rather than a new headline; Viking had previously reported up to 14.7% mean weight loss at 13 weeks. It also noted shares were below the 50-day and 200-day moving averages.
UBS Just Initiated Coverage of Viking Therapeutics With a Buy Rating and a $94 Target. Here's the Bull Case.
UBS initiated coverage of Viking Therapeutics on Oct. 14 with a Buy rating and a 12-month price target of $94. [[fact-xgpa6ds7y]] In Viking’s phase 2 Venture trial, its injectable treatment produced average weight reductions of up to 14.7% after 13 weekly doses. [[fact-upk944nnj]] Earlier phase 2 results showed that patients taking oral VK2735 lost up to 12.2% of their body weight after 13 weeks. [[fact-x1r98iyw5]] Viking announced on Oct. 14 that it had initiated the Phase 3 Sunrise clinical program for oral VK2735. [[fact-kv066hacc]]
Viking Therapeutics Reports Renewed Takeover Interest
Viking Therapeutics shares rose following reports of renewed takeover interest in the clinical-stage biopharmaceutical company.
Viking reports VK2735 Phase 2 VENTURE analysis at ObesityWeek
At ObesityWeek, held Nov. 14–17, Viking reported that after 13 weeks, 74% of participants receiving weekly subcutaneous VK2735 improved by at least one BMI category, versus 15% on placebo. The company also reported improvements in cardiometabolic markers; up to 14.7% mean weight reduction and 92% of drug-related adverse events mild or moderate were previously reported for VENTURE.
Viking Therapeutics Highlights Clinical Data from VK2735 Obesity Program at ObesityWeek® 2026
At ObesityWeek on Nov. 15, 2026, Viking reported a Phase 2 VENTURE analysis: after 13 weeks, 74% of participants receiving subcutaneous VK2735 improved by at least one BMI category, versus 15% on placebo; no VK2735-treated participant moved to a higher category. The analysis also found improvements across multiple cardiometabolic markers. Positive clinical update; no negative company-specific item
Viking Therapeutics Announces Two Poster Presentations at ObesityWeek® 2026
Viking Therapeutics Announces Two Poster Presentations at ObesityWeek® 2026(摘要待生成)
Viking Therapeutics Trades 23% Below Its Own $35 Secondary Offering Price. Here's Why That Could Be a Gift for Patient Investors.
Viking Therapeutics Trades 23% Below Its Own $35 Secondary Offering Price. Here's Why That Could Be a Gift for Patient Investors.(摘要待生成)
Viking Therapeutics to Participate at Upcoming Investor Conferences
Viking Therapeutics to Participate at Upcoming Investor Conferences(摘要待生成)
VKTX Stock Slides Overnight After Q3 Loss: CEO’s Obesity Drug Launch Timeline Frustrates Retail - Yahoo Finance
VKTX Stock Slides Overnight After Q3 Loss: CEO’s Obesity Drug Launch Timeline Frustrates Retail - Yahoo Finance(摘要待生成)